A Randomized, Double-Blind, Controlled Phase I Trial to Evaluate the Safety, Tolerability, and Immunogenicity of DCB07010 Adjuvant Given Intranasally at Ascending Dose Levels and Co-Administered with Trivalent Inactivated Influenza Virus Antigen (II)